<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886067</url>
  </required_header>
  <id_info>
    <org_study_id>D1950C00004</org_study_id>
    <secondary_id>EudraCT No. 2008-008390-55</secondary_id>
    <nct_id>NCT00886067</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Study</brief_title>
  <official_title>An Open-label Positron Emission Tomography (PET) Study Using 2 [18F] F A85380 to Determine α4β2 Neuronal Nicotinic Receptor (NNR) Occupancy of AZD1446 After Oral Administration to Male and Non-fertile Female (Non-nicotine Users) Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to study the occupancy at the α4β2 neuronal nicotinic receptor's
      (NNRs) and to determine the relation between plasma concentration of AZD1446 and the
      occupancy at α4β2 NNRs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether and to what extent AZD1446 can displace radioligand 2-[18F]-F-A85380 from binding to α4β2 neuronal nicotinic receptors (NNRs) and to describe the relationship between plasma concentrations of AZD1446 and its occupancy at α4β2 NNRs.</measure>
    <time_frame>One PET assessment on baseline day and one PET assessment at the drug treatment day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration (Cmax, tmax, AUC)</measure>
    <time_frame>During time period of the PET assessment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (AEs, vital signs, lab)</measure>
    <time_frame>During the whole study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>2-[18F]-F-A85380</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single microdose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1446</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1446</intervention_name>
    <description>Solution, oral, single dose</description>
    <arm_group_label>AZD1446</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>2-[18F]-F-A85380</intervention_name>
    <description>iv, single dose</description>
    <arm_group_label>2-[18F]-F-A85380</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physically healthy volunteers

          -  Body weight between 50 to 100 kg and body mass index (BMI) between 19 and 30 kg/m2

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  History of severe allergy/hypersensitivity reactions

          -  Participation in a PET examination as part of a scientific study during the past
             twelve months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Björn Paulsson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Södertälje</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingemar , Bylesjö, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca CPU Huddinge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>AstraZeneca</name_title>
  </responsible_party>
  <keyword>AZD1446</keyword>
  <keyword>PET examination</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

